Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Acriflavinium→

Acriflavinium Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
8048-52-0
Molecular formula
C14H14N3+
Molecular weight
224.28 g/mol
Drug class
Acridine dye antiseptictopical antimicrobial agent
Mechanism of action
Interacts with microbial nucleic acids and cellular components, inhibiting microbial replication and growth. It is used locally as an antiseptic; exact activity depends on concentration and formulation.
Indications / reported uses
  • Topical antiseptic use in selected superficial skin and wound-care preparations in countries where acriflavinium products remain authorised; not a systemic antibacterial indication

Sources: NLM MeSH — Acriflavine · PubMed — Acriflavine antimicrobial activity · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Acridine dye antiseptic; topical antimicrobial agent

Mechanism of action

Interacts with microbial nucleic acids and cellular components, inhibiting microbial replication and growth. It is used locally as an antiseptic; exact activity depends on concentration and formulation.

General use cases

  • Topical antiseptic use in selected superficial skin and wound-care preparations in countries where acriflavinium products remain authorised; not a systemic antibacterial indication

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Acriflavinium Environmental Risk Assessment (ERA) (the Acriflavinium ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.